期刊文献+

子宫内膜癌组织中Galectin-9、CD44v6的表达及相关性分析 被引量:2

Expressions and correlation analysis of Galectin-9 and CD44v6 in endometrial carcinoma
原文传递
导出
摘要 目的研究子宫内膜癌组织中半乳凝素-9 (Galectin-9)、CD44v6的表达及相关性,为临床子宫内膜癌的早期诊断、治疗及预后评估提供参考依据。方法以2016年2月-2018年2月解放军313医院收治的子宫内膜癌患者86例为研究对象,分别采集患者子宫内膜癌组织以及癌旁正常组织。采用免疫组织化学法检测不同子宫内膜组织中Galectin-9、CD44v6的表达情况,并分析Galectin-9、CD44v6表达与子宫内膜癌患者临床病理特征的关系。结果子宫内膜癌组织中Galectin-9、CD44v6阳性率分别为82. 56%、80. 23%,均高于癌旁正常组织的31. 40%、24. 42%,差异均有统计学意义(均P<0. 05)。临床分期为Ⅲ~Ⅳ期、浸润深度≥浅肌层、有淋巴结转移的子宫内膜癌患者Galectin-9阳性率、CD44v6阳性率高于临床分期为Ⅰ~Ⅱ期、浸润深度<浅肌层、无淋巴结转移患者,差异均有统计学意义(均P<0. 05)。经Spearman相关性分析可知子宫内膜癌组织中Galectin-9、CD44v6表达存在正相关关系(r=0. 633,P=0. 000)。结论子宫内膜癌组织中Galectin-9、CD44v6均呈明显高表达,且与患者临床分期、淋巴结转移存在密切相关。临床工作中可通过联合检测上述两项指标表达情况,从而有利于判断子宫内膜癌患者病情以及淋巴结转移情况。 Objective To study the expressions and correlation of Galectin-9 and CD44 v6 in endometrial carcinoma,provide a reference basis for early diagnosis,treatment,and prognosis evaluation of endometrial carcinoma.Methods From February 2016 to February2018,86 patients with endometrial carcinoma treated in the 313 rd Hospital of PLA were selected,endometrial carcinoma tissue samples and normal endometrial tissue samples adjacent to endometrial carcinoma were collected,immunohistochemistry was used to detect the expressions of Galectin-9 and CD44 v6 in the two groups,the relationships between expressions of Galectin-9 and CD44 v6 and clinicopathological characteristics of patients with endometrial carcinoma were analyzed.Results The positive rates of Galectin-9 and CD44 v6 in endometrial carcinoma group were 82.56%and 80.23%,respectively,which were statistically significantly higher than those in normal tissue adjacent to endometrial carcinoma(31.40%and 24.42%)(P<0.05).The positive rates of Galectin-9 and CD44 v6 in patients with clinical stageⅢ-Ⅳ,infiltration depth≥superficial myometrium,lymph node metastasis were statistically significantly higher than those in patients with clinical stageⅠ-Ⅱ,infiltration depth<superficial myometrium,lack of lymph node metastasis(P<0.05).Spearman correlation analysis showed that there was a positive correlation between Galectin-9 expression and CD44 v6 expression in endometrial carcinoma(r=0.633,P=0.000).Conclusion Galectin-9 and CD44 v6 are highly expressed in endometrial carcinoma,which are closely related to clinical stage and lymph node metastasis.Joint detection of Galectin-9 and CD44 v6 can judge the condition of patients with endometrial carcinoma and lymph node metastasis.
作者 张宇靖 腾红 郭珊珊 周炫妤 ZHANG Yu-Jing;TENG Hong;GUO Shan-Shan(Department of Gynecology and Obstetrics,the 313rd Hospital of PLA,Huludao,Liaoning 125001,China)
机构地区 解放军第
出处 《中国妇幼保健》 CAS 2019年第17期4070-4073,共4页 Maternal and Child Health Care of China
基金 辽宁省自然科学基金项目(2015020823)
关键词 子宫内膜癌 半乳凝素-9 CD44V6 相关性分析 临床病理特征 Endometrial carcinoma Galactin-9 CD44v6 Correlation analysis Clinicopathological characteristic
  • 相关文献

参考文献10

二级参考文献85

  • 1安宁,王建军.半乳凝素-9蛋白在肺腺癌、鳞癌中的表达及意义[J].中华临床医师杂志(电子版),2011,5(24):7374-7376. 被引量:3
  • 2Andreasen PA,Kjoller L,Christensen L,et al.The urokinase-type plasminogen activator system in cancer metastasis:a review[J].International Journal of Cancer,1997,72:1-22.
  • 3Tanaka N,Fukao H,Ueshima S,et al.Plasminogen activator inhibitor 1 in human carcinoma tissues[J].International Journal of Cancer,1991,48:481-484.
  • 4MayerhoferK,Stolzlechner J,Yildiz S,et al.Plasminogen activator inhibitor 1 and prognosis in breast carcinoma[J].Geburtshilfe Frauenheikd,1996,56:23-27.
  • 5MuehlenwegB,Sperl S,Magdolen V,et al.Interference with the urokinase plasminogen activator system:a promising therapy concept for solid tumours[J].Expert Opinion on Biological Therapy,2001,1:683-691.
  • 6RomerJ,Nielsen BS,Ploug M.The urokinase receptor as a potential target in cancer therapy[J].Current Pharmaceutical Design,2004,10:2359-2376.
  • 7Andreasen PA,Andersen JA,Hansen S,et al.Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer[J].British Journal of Cancer,1998,77:932-940.
  • 8Harbeck N,Kates RE,Gauger K,et al.Urokinasetype plasminogen activator (uPA) and its inhibitor PAI-Ⅰ:novel tumor-derived factors with a high prognostic and predictive impact in breast cancer[J].Thrombosis and Haemostasis,2004,91:450-456.
  • 9Janicke F,Prechtl A,Thomssen C,et al.Randomized adjuvant chemotherapy trial in high-risk,lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1[J].Journal of the National Cancer Institute,2001,93:913-920.
  • 10Croucher DR,Saunders DN,Stillfried GE,et al.A structural basis for differential cell signalling by PAI-l and PAI-2 in breast cancer cells[J].The Biochemical Journal,2007,408:203-210.

共引文献51

同被引文献23

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部